NewsBenzingaInformado el domingo, Divarasib de Genentech reduce el riesgo de muerte un 44% en la fase III Krascendo 1, con menos interrupciones por TRAE (4,8% frente a 11,7%) que sotorasib o adagrasib en NSCLC KRAS G12C previamente tratado Informado el domingo, Divarasib de Genentech reduce el riesgo de muerte un 44% en la fase III Krascendo 1, con menos interrupciones por TRAE (4,8% frente a 11,7%) que sotorasib o adagrasib en NSCLC KRAS G12C previamente tratado Benzinga 2026.10.26 07:28 (GMT+0) Open on Benzinga Other news David Einhorn Bets on Aluminum in Q3: Here Are His New Stock Picks, Fund Changes Bernstein Maintains Market Perform on Tyson Foods, Raises Price Target to $72 Broadcom Stock Is Up Tuesday: AI Chip Diversification, Dec. 9 Earnings, Analyst Targets SharonAI Analysts Cut Their Forecasts Following Q3 Results Bernstein Downgrades PepsiCo to Underperform, Lowers Price Target to $128 If You Invested $1000 In Humana Stock 20 Years Ago, You Would Have This Much Today